摘要
目的研讨在治疗失代偿期乙肝肝硬化中实行恩替卡韦的临床效果。方法选取近年我院收治的24例患者参与研究,对所有患者均给予常规治疗,并且同时予以恩替卡韦,对比分析治疗前后患者的临床效果。结果治疗后患者并发症发生率41.66%、ALB为(32.27±2.37)g/L、TBIL为(29.28±3.27)μmol/L,评分均优于治疗前患者并发症发生率8.33%、ALB为(39.54±3.58)g/L、TBIL为(20.47±2.89)μmol/L,P<0.05,差异具有统计学意义。结论将恩替卡韦应用在失代偿期乙肝肝硬化治疗中具有显著效果,可以降低并发症发生率,改善治疗后效果。
Objective To study the treatment of decompensated period in hepatitis b cirrhosis of the liver on the clinical effect of entecavir. Methods24 patients participated were selected in our hospital, all patients were given routine treatment, and at the same time be entecavir, comparative analysis of the clinical effect of patients before and after treatment. Results After treatment, the incidence of complications was 41.66%, ALB score（32.27±2.37） g/L, TBIL（29.28±3.27） μmol/L, scores were better than the incidence of 8.33%, ALB score of patients before treatment of complications（39.54±3.58） g/L, TBIL score（20.47±2.89） μmol/L, P〈0.05, the difference was statistically significant. Conclusion Entecavir application has significant effect in the treatment of decompensated hepatitis B cirrhosis, can reduce the incidence of complications, improve the therapeutic effect.
出处
《中国继续医学教育》
2016年第30期137-138,共2页
China Continuing Medical Education
关键词
恩替卡韦
失代偿期乙肝肝硬化
效果
Entecavir
Decompensated period of hepatitis b cirrhosis of the liver
Effect
